Keyphrases
Multiple Sclerosis
100%
Natalizumab
43%
Natalizumab Treatment
33%
Multiple Sclerosis Treatment
33%
Disease Activity
32%
Relapsing-remitting multiple Sclerosis
24%
Treatment Response
22%
Body Mass Index
22%
Obesity
21%
Energy Expenditure
21%
Control Energy
21%
Energy Intake
21%
Interferon-β (IFN-β)
16%
B Cells
15%
T Helper 17 (Th17)
14%
Interferon-β Treatment
13%
Relapse Rate
13%
Smokers
13%
Immune Activation
13%
CD4+ T Cells
12%
Risk Variant
12%
T Cells
12%
Healthy Controls
12%
Non-associated
12%
Risk Factors
12%
MS Patients
11%
Relapsing-remitting MS
11%
University of Pennsylvania
10%
Perelman
10%
Biostatistics
10%
Plasmablast
10%
Neurofilament Light (NF-L)
10%
Healthy Individuals
10%
Relapse Risk
10%
GPR15
10%
Weighted Genetic Risk Score
10%
Genetic Burden
10%
CD20+ T Cells
10%
Perfluorinated Substances
10%
Melanoma Cell Adhesion Molecule
10%
Cell Adhesion Molecule 1 (CADM1)
10%
Blood mRNA
10%
Tumefactive multiple Sclerosis
10%
ORCID
10%
Incidence Rate
10%
Interleukin-12 (IL-12)
10%
Interleukin-6
10%
Lymphocytes
10%
Philadelphia
10%
Human Leukocyte antigen-A
10%
Immunology and Microbiology
Multiple Sclerosis
86%
Natalizumab
32%
T Cell
25%
B Cell
19%
T-Helper Cell
18%
Relapsing Remitting Multiple Sclerosis
15%
CD20
10%
CD146 Antigen
10%
Myelin
10%
Interleukin-6
10%
ELISA
10%
Lymphocyte
10%
VCAM-1
10%
Genetic Risk
10%
Plasmablast
10%
Beta Interferon
10%
Cell Adhesion Molecule 1
10%
Cerebrospinal Fluid
10%
Immunocompetent Cell
10%
Blood Plasma
8%
STAT3
8%
Human Leukocyte Antigen
8%
CXCR3
7%
Blood Level
6%
Neuroscience
Multiple Sclerosis
86%
Natalizumab
54%
T Cell
25%
Human Leukocyte Antigen
19%
Relapsing Remitting Multiple Sclerosis
18%
B Cell
16%
CD4
13%
Beta Interferon
12%
Lymphocyte
10%
Neurofilament Light Chain
10%
GPR15
10%
Cell Adhesion Molecule 1
10%
CD146 Antigen
10%
VCAM-1
10%
STAT3
8%
Magnetic Resonance Imaging
8%
N-Acetyltransferase
6%
